Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
The newly approved treatment, SKINVIVE by JUVÉDERM, is now the first and only hyaluronic acid injectable cleared specifically for improving neck appearance
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
Broadening access for children & patients with inhibitor-complicated hemophilia
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
